Media coverage
43
Media coverage
Title Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection Media name/outlet National AIDS Treatment Advocacy Project Country United States Date 11/18/16 Persons Eric J Lawitz Title Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection Media name/outlet PipelineReview Country Spain Date 11/14/16 Persons Eric J Lawitz Title Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection Media name/outlet TMC Net Country United States Date 11/13/16 Persons Eric J Lawitz Title Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection Media name/outlet Nasdaq Country United States Date 11/13/16 Persons Eric J Lawitz Title Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection Media name/outlet India Pharma News Country India Date 11/13/16 Persons Eric J Lawitz Title Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection Media name/outlet Yahoo! Finance UK and Ireland Date 11/13/16 Persons Eric J Lawitz Title Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection Media name/outlet Presentation Master Country United States Date 11/13/16 Persons Eric J Lawitz Title Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection Media name/outlet Pharmacy Choice Country United States Date 11/13/16 Persons Eric J Lawitz Title Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection Media name/outlet Stock Nod Country United States Date 11/13/16 Persons Eric J Lawitz Title Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection Media name/outlet Business Wire Country United States Date 11/13/16 Persons Eric J Lawitz Title Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection Media name/outlet Channel 8 Eyewitness News Country United States Date 11/13/16 Persons Eric J Lawitz Title Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection Media name/outlet CW Richmond WUPV Country United States Date 11/13/16 Persons Eric J Lawitz Title Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection Media name/outlet 35 WSEE Country United States Date 11/13/16 Persons Eric J Lawitz Title Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection Media name/outlet Fox 19 Country United States Date 11/13/16 Persons Eric J Lawitz Title Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection Media name/outlet WLBT Country United States Date 11/13/16 Persons Eric J Lawitz Title Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection Media name/outlet WOWK Country United States Date 11/13/16 Persons Eric J Lawitz Title Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection Media name/outlet WBOC TV 16 Country United States Date 11/13/16 Persons Eric J Lawitz Title Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection Media name/outlet WALB 10 Country Georgia Date 11/13/16 Persons Eric J Lawitz Title Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection Media name/outlet WLTZ 38 Country Georgia Date 11/13/16 Persons Eric J Lawitz Title Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection Media name/outlet KTRE Country United States Date 11/13/16 Persons Eric J Lawitz Title Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection Media name/outlet Kuam News 8 Country Guam Date 11/13/16 Persons Eric J Lawitz Title Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection Media name/outlet KPTV.com Country United States Date 11/13/16 Persons Eric J Lawitz Title Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection Media name/outlet KCBD Country United States Date 11/13/16 Persons Eric J Lawitz Title Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection Media name/outlet KTVN Country United States Date 11/13/16 Persons Eric J Lawitz Title Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection Media name/outlet Kait 8 Country United States Date 11/13/16 Persons Eric J Lawitz Title Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection Media name/outlet NewsChannel 10 Country United States Date 11/13/16 Persons Eric J Lawitz Title Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection Media name/outlet KSLA Country United States Date 11/13/16 Persons Eric J Lawitz Title Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection Media name/outlet KAUZ Country United States Date 11/13/16 Persons Eric J Lawitz Title Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection Media name/outlet WTRF Country United States Date 11/13/16 Persons Eric J Lawitz Title Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection Media name/outlet KOTV Country United States Date 11/13/16 Persons Eric J Lawitz Title Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection Media name/outlet KFVS12 Country United States Date 11/13/16 Persons Eric J Lawitz Title Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection Media name/outlet WSFA Country United States Date 11/13/16 Persons Eric J Lawitz Title Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection Media name/outlet WMBF Country United States Date 11/13/16 Persons Eric J Lawitz Title Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection Media name/outlet Fox 8 WVUE New Orleans Country United States Date 11/13/16 Persons Eric J Lawitz Title Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection Media name/outlet KUSI.com Country United States Date 11/13/16 Persons Eric J Lawitz Title Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection Media name/outlet WFLX Fox 29 Country United States Date 11/13/16 Persons Eric J Lawitz Title Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection Media name/outlet KSWO Country United States Date 11/13/16 Persons Eric J Lawitz Title Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection Media name/outlet KHQ Right Now Country United States Date 11/13/16 Persons Eric J Lawitz Title Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection Media name/outlet WVNS Country United States Date 11/13/16 Persons Eric J Lawitz Title Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection Media name/outlet Hawaii News Now Country United States Date 11/13/16 Persons Eric J Lawitz Title Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection Media name/outlet WLOX Country United States Date 11/13/16 Persons Eric J Lawitz Title Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection Media name/outlet WTVM Country Georgia Date 11/13/16 Persons Eric J Lawitz Title Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection Media name/outlet KXXV-TV Country United States Date 11/13/16 Persons Eric J Lawitz